Australia's Telehealth Loophole: A Prescription for Controversy
The rise of telehealth has revolutionized healthcare access, but a recent surge in online prescriptions, especially for medicinal cannabis, has exposed a legal loophole with alarming implications.
Therapeutic Goods Administration's (TGA) chief medical advisor, Robyn Langham, has issued a stark warning about the exploitation of telehealth regulations by clinics, which has led to a concerning shift in Australia's prescription drug landscape. Langham's remarks, made at a seminar and later removed from YouTube, highlight the growing trend of recreational access to medicinal cannabis, rather than genuine medical need.
But here's where it gets controversial: Companies have found and exploited loopholes in cannabis prescribing rules, leading to a flood of prescriptions. Langham noted that the regulatory framework surrounding cannabis, approved for medicinal use a decade ago, is now inadequate.
A special access scheme allows practitioners to prescribe cannabis, but Langham argues it was intended for unique situations, not the current widespread use. The result? A staggering 6.59 million units of legal medicinal cannabis products sold in Australia last year, with telehealth platforms automating consultations and prioritizing prescription volumes.
The telehealth model, which gained traction during the pandemic, has become a national market with diverse players. From weight-loss drugs to cosmetic injectables and ADHD diagnoses, the range of services is expanding rapidly.
Striking a balance between patient access and safety is crucial, as acknowledged by the TGA and Federal Health Minister Mark Butler. Telehealth has been a game-changer for rural patients, but the lack of oversight has led to serious concerns. Butler emphasizes the need for quality controls, especially regarding the closed-loop business models in the medicinal cannabis sector.
The TGA's review of medicinal cannabis prescription rules aims to determine the actual prescription volume, which is currently unclear due to various prescription methods. The Australian Health Practitioner Regulation Agency (AHPRA) has also warned about practitioners prioritizing profits over patient welfare, targeting those overprescribing.
One notable case is Dr. Justin Welsh, a South Melbourne doctor, who was suspended from prescribing medicinal cannabis to his 4000+ patients due to the volume of his prescriptions. Welsh argues that he is serving a patient group neglected by regulators, preventing them from turning to the black market. He criticizes AHPRA's enforcement, claiming it ignores the regulatory void created when medicinal cannabis was legalized without anticipating the demand.
Welsh's suspension, prompted by state health complaints, highlights the challenges of inconsistent state regulations for telehealth doctors. The lack of standardized dosing and overdose guidelines further complicates the issue.
Welsh believes the real danger lies in the unregulated cannabis market, where street marijuana poses health risks. He claims medicinal cannabis is safer and often cheaper than illegal alternatives.
Welsh's suspension has left patients in limbo, causing distress and uncertainty. The Penington Institute's annual report reveals plateauing medicinal cannabis sales in 2025, with edible products gaining popularity. The report also highlights Australia's reliance on imported medicinal cannabis, sidelining domestic growers.
As the debate rages on, one question remains: How can Australia strike a balance between patient access and safety in the evolving telehealth landscape?
